We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Recommends PTC Therapeutics’ DMD Drug Translarna
NICE Recommends PTC Therapeutics’ DMD Drug Translarna
The UK’s drug pricing watchdog is recommending reimbursement of PTC Therapeutics’ Translarna to treat Duchenne muscular dystrophy, provided the company complies with an access agreement.